open access

Vol 94, No 7 (2023)
Review paper
Published online: 2022-09-21
Get Citation

Severe course of COVID-19 in pregnant woman and newborn’s alloimmune thrombocytopenia — case study and review of the literature

Angelika Piotrowska-Gwizdak1, Karolina Krajewska1, Hanna Blaszczyk1, Anna Gluszko2, Konstanty Szuldrzynski3, Waldemar Wierzba4, Artur J. Jakimiuk15
·
Pubmed: 36134762
·
Ginekol Pol 2023;94(7):565-569.
Affiliations
  1. Department of Obstetrics and Gynecology, Central Clinical Hospital of the Ministry of the Interior and Administration (MSWiA), Warsaw, Poland
  2. Department of Neonatology, Central Clinical Hospital of the Ministry of the Interior and Administration (MSWiA), Warsaw, Poland
  3. Department of Anaesthesiology and Intensive Therapy, Central Clinical Hospital of the Ministry of the Interior and Administration (MSWiA), Warsaw, Poland
  4. University of Humanities and Economics, Lodz, Satellite Campus in Warsaw, Poland
  5. Center of Reproductive Health, Institute of Mother and Child, Warsaw, Poland

open access

Vol 94, No 7 (2023)
REVIEW PAPERS Obstetrics
Published online: 2022-09-21

Abstract

So far, little is known about the impact of the coronavirus disease 2019 (COVID-19) on pregnancy and data is often inconsistent. Even less information has been published on the management of severe courses of COVID-19 in pregnant women. By writing this article, we aim to share our experience in the treatment of pregnant woman critically ill with COVID-19 and newborn’s condition, fetal and neonatal alloimmune thrombocytopenia (FNAIT), as well as literature review of this disease. After admission, the woman’s respiratory status rapidly worsened, requiring administration of oxygen and in the end ECMO therapy. At the 9th day of ECMO support, and 28 weeks 3 days of gestation, due to mother’s prognosis and increased feto-placental vascular resistance a decision of Caesarean section was taken. The neonate required intensive care not only due to extreme prematurity but coagulation disorder, alloimmune thrombocytopenia, which we diagnosed a few weeks after delivery.

Abstract

So far, little is known about the impact of the coronavirus disease 2019 (COVID-19) on pregnancy and data is often inconsistent. Even less information has been published on the management of severe courses of COVID-19 in pregnant women. By writing this article, we aim to share our experience in the treatment of pregnant woman critically ill with COVID-19 and newborn’s condition, fetal and neonatal alloimmune thrombocytopenia (FNAIT), as well as literature review of this disease. After admission, the woman’s respiratory status rapidly worsened, requiring administration of oxygen and in the end ECMO therapy. At the 9th day of ECMO support, and 28 weeks 3 days of gestation, due to mother’s prognosis and increased feto-placental vascular resistance a decision of Caesarean section was taken. The neonate required intensive care not only due to extreme prematurity but coagulation disorder, alloimmune thrombocytopenia, which we diagnosed a few weeks after delivery.

Get Citation

Keywords

pregnancy; COVID-19; ECMO; FNAIT

About this article
Title

Severe course of COVID-19 in pregnant woman and newborn’s alloimmune thrombocytopenia — case study and review of the literature

Journal

Ginekologia Polska

Issue

Vol 94, No 7 (2023)

Article type

Review paper

Pages

565-569

Published online

2022-09-21

Page views

1214

Article views/downloads

430

DOI

10.5603/GP.a2022.0083

Pubmed

36134762

Bibliographic record

Ginekol Pol 2023;94(7):565-569.

Keywords

pregnancy
COVID-19
ECMO
FNAIT

Authors

Angelika Piotrowska-Gwizdak
Karolina Krajewska
Hanna Blaszczyk
Anna Gluszko
Konstanty Szuldrzynski
Waldemar Wierzba
Artur J. Jakimiuk

References (17)
  1. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr. 2020; 8: 104.
  2. Allotey J, Stallings E, Bonet M, et al. for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; 370: m3320.
  3. Szczygiol P, Baranska K, Korczak I, et al. COVID-19 in pregnancy, management and outcomes among pregnant women and neonates — results from tertiary care center in Wroclaw. Ginekol Pol. 2022; 93(1): 47–53.
  4. Nayak MK, Panda SK, Panda SS, et al. Neonatal outcomes of pregnant women with COVID-19 in a developing country setup. Pediatr Neonatol. 2021; 62(5): 499–505.
  5. Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO J. 2020; 66(5): 472–474.
  6. Barrantes JH, Ortoleva J, O'Neil ER, et al. Successful Treatment of Pregnant and Postpartum Women With Severe COVID-19 Associated Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. ASAIO J. 2021; 67(2): 132–136.
  7. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020; 396(10257): 1071–1078.
  8. Brojer E, Husebekk A, Dębska M, et al. Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention. Arch Immunol Ther Exp (Warsz). 2016; 64(4): 279–290.
  9. Peterson JA, McFarland JG, Curtis BR, et al. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013; 161(1): 3–14.
  10. Winkelhorst D, de Vos TW, Kamphuis MM, et al. HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk. BMJ Open. 2020; 10(7): e034071.
  11. Kamphuis MM, Paridaans NP, Porcelijn L, et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014; 133(4): 715–721.
  12. Bertrand G, Drame M, Martageix C, et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood. 2011; 117(11): 3209–3213.
  13. Uhrynowska ME, Dębska M, Guz K, et al. [PREVFNAIT prevention of foetal/neonatal alloimmune thrombocytopenia (FNAIT) in Polish foetuses and newborns--the PREVFNAIT program]. Ginekol Pol. 2015; 86(1): 62–66.
  14. Lieberman L, Greinacher A, Murphy MF, et al. International Collaboration for Transfusion Medicine Guidelines (ICTMG). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019; 185(3): 549–562.
  15. Winkelhorst D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017; 129(11): 1538–1547.
  16. Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2021; 225(2): 120–127.
  17. de Vos TW, Winkelhorst D, de Haas M, et al. Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci. 2020; 59(1): 102704.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl